Cytoplasmic localization of Mdm2 in cells expressing mutated NPM is mediated by p53

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Specific C-terminal nucleophosmin (NPM) mutations are linked to acute myeloid leukemia (AML).
• Mutated NPM (NPMmut) is mistargeted to the cytoplasm, causing mislocalization of its interacting partners, including the tumor suppressor p53.
• Ubiquitin ligase Mdm2, an interactor of p53, also mislocalizes to the cytoplasm in the presence of NPMmut.

Purpose of the Study:

• To investigate the formation and structure of a potential ternary complex involving NPMmut, p53, and Mdm2.
• To elucidate the interaction dynamics between NPMmut, p53, and Mdm2 in live cells and cell lysates.
• To understand the role of p53 as a potential bridging molecule in this complex.

Main Methods:

• Utilized fluorescently tagged proteins to visualize interactions in live cells.
• Employed fluorescence lifetime imaging (FLIM) to study molecular interactions.
• Performed immunoprecipitation assays to confirm protein complex formation.

Main Results:

• Confirmed the existence of a ternary complex comprising NPMmut, p53, and Mdm2, likely adopting a chain-like configuration.
• Found no direct interaction between Mdm2 and NPMmut, even under conditions that upregulate Mdm2 and p53.
• Demonstrated that p53 acts as a bridge between Mdm2 and NPMmut; disruption of Mdm2-p53 interaction by Nutlin-3A caused Mdm2 nuclear relocalization, while NPMmut and p53 remained cytoplasmic.
• Showed that silencing p53 prevented Mdm2 mislocalization in the presence of NPMmut.

Conclusions:

• p53 plays a crucial role as a bridging molecule in the NPMmut-p53-Mdm2 ternary complex.
• The formation of this complex is responsible for the cytoplasmic mislocalization of Mdm2 in AML cells with specific NPM mutations.
• Targeting the p53-Mdm2 interaction could be a potential therapeutic strategy for AML associated with NPM mutations.